I have been on Lenvima (lenvatinib) 10 mg daily for 5 years and my thyroglobulin level is now 399 ng/mL; what is the appropriate next step in management?

Assess for Disease Progression and Consider Second-Line Therapy

With a thyroglobulin level of 399 ng/mL after 5 years on Lenvima 10 mg daily, you should immediately obtain cross-sectional imaging (CT chest/abdomen/pelvis or PET-CT) to assess for structural disease progression, and if confirmed, transition to cabozantinib as second-line therapy.

Immediate Evaluation Required

Your rising thyroglobulin (Tg) to 399 ng/mL signals potential disease progression. The critical next steps are:

• Obtain imaging within 2-4 weeks: CT chest/abdomen/pelvis with contrast or PET-CT to assess structural disease status 1
• Calculate Tg doubling time: This helps predict outcomes and urgency of intervention 2
• Assess clinical symptoms: Progressive dyspnea, bone pain, or other symptoms indicating symptomatic metastases

Understanding Your Current Situation

After 5 years on lenvatinib, several scenarios are possible:

If imaging shows progression:

• This represents acquired resistance to lenvatinib, which is expected over time
• The median progression-free survival with lenvatinib is approximately 21-25 months 2, 3, so progression at 5 years indicates you've had an excellent response duration

If imaging shows stable disease despite rising Tg:

• Tg elevation alone without structural progression may not require immediate treatment change
• Continue lenvatinib with closer monitoring (imaging every 2-3 months)

Second-Line Treatment: The Evidence-Based Choice

Cabozantinib is the recommended second-line therapy after lenvatinib progression 1:

• Phase III trial data shows median PFS of 11.0 months vs 1.9 months with placebo (HR 0.22) after progression on lenvatinib/sorafenib
• This is a Category 1 recommendation for papillary thyroid cancer 1
• Objective response rate: 11% vs 0% with placebo
• Works regardless of whether you had papillary, follicular, or oncocytic histology 1

Alternative Options if Cabozantinib Unavailable

Pembrolizumab added to lenvatinib 1:

• If you're tolerating lenvatinib well with manageable side effects
• 16% objective response rate when added to lenvatinib after progression
• Median PFS: 10.0 months
• Consider this if you cannot tolerate a second tyrosine kinase inhibitor

Other considerations:

• If you have BRAF V600E mutation: Dabrafenib + trametinib combination 4
• If you have oligoprogression (1-3 sites): Local ablative therapy (surgery, radiation, radiofrequency ablation) while continuing lenvatinib 3

Critical Pitfalls to Avoid

1. Don't continue lenvatinib indefinitely without imaging confirmation: Rising Tg alone isn't sufficient to make treatment decisions 2

2. Don't assume dose escalation will work at this point: While dose escalation can be effective for early progression 5, after 5 years of therapy, you've likely developed true resistance requiring a different mechanism of action

3. Don't delay imaging: Symptomatic progression or rapid Tg rise requires urgent evaluation to prevent complications from untreated metastases

4. Don't stop lenvatinib before starting next therapy: If you have progressive disease, maintain disease control until second-line therapy is initiated

Monitoring During Transition

Once you confirm progression and plan treatment change:

• Baseline labs before cabozantinib: CBC, comprehensive metabolic panel, thyroid function, urinalysis for proteinuria 1
• Blood pressure control: Must be optimized before starting cabozantinib 1
• Dental evaluation: Complete any needed dental work before starting cabozantinib due to osteonecrosis risk 6

If No Progression on Imaging

If imaging shows stable disease despite Tg 399:

• Continue lenvatinib at current dose
• Repeat imaging in 2-3 months
• Monitor Tg monthly
• Calculate tumor growth slope (TGS) - this predicts outcomes better than Tg alone 2

The key is that structural progression on imaging, not Tg alone, should drive the decision to change therapy 4. Your 5-year duration on lenvatinib represents an exceptional response, but acquired resistance is expected and manageable with evidence-based second-line options.